Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 76K adjuvant nivolumab versus placebo in resected stage IIB/C melanoma
NL-OMON60386Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Nivolumab with Placebo (2 arms). Primary endpoint: Recurrence-free survival. Started Aug 2020; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON60386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60386.